The 7th Edition of TNM in Lung Cancer: What Now?  by Goldstraw, Peter
EDITORIAL
The 7th Edition of TNM in Lung Cancer: What Now?
Peter Goldstraw, MB, FRCS
The long-awaited 7th edition of tumor, node, metastasis (TNM) in Lung Cancer has nowbeen published by the International Union Against Cancer and the American Joint
Committee on Cancer. The changes to the 6th edition were based upon proposals from the
International Staging Project of the International Association for the Study of Lung
Cancer (IASLC).1 As required by the internal review processes of the two bodies that
administer the TNM classification these proposals were finalized and submitted early in
2007. Since that time, the detailed proposals have been published in no less than 13
articles in the Journal of Thoracic Oncology.2–14 As chair of the International Staging
Project I have made almost 50 presentations in 21 countries spanning 5 continents, and the
other members of the committee have given many additional presentations. Surely, the
most telegraphed changes to the TNM classification ever!
So what are the changes in the 7th edition? Broadly speaking they are:
a. Size cut points, in addition to the 3 cm cut point that traditionally separated T1 and T2
tumors, have been introduced at 2, 5, and 7 cm. T1 tumors are now subdivided into T1a
and T1b around the 2 cm cut point. T2 tumors have been subdivided into T2a and T2b
around the 5 cm cut point, and tumors 7 cm are now classified as T3.2
b. Cases in which additional tumor nodules are found have been reclassified. Those in the
same lobe as the primary tumor are now classified as T3, those in the other ipsilateral
lobe(s) are T4 and those in the opposite lung are now M1a.2,4
c. Cases associated with pleural or pericardial nodules/effusions have been reclassified
from T4 to M1a.4
d. M1 disease due to distant metastases has been reclassified as M1b.4
e. The utility of the TNM classification in small-cell lung cancer has been confirmed in the
largest data base of such cases ever established, treated by all modalities of care.7,14
f. The validity of TNM in Carcinoid tumors has been shown and these are now included,
for the first time, within the TNM classification.9
g. A new IASLC nodal chart, with precise definitions, has been agreed, reconciling the
previous differences between the Japanese and Mountain-Dresler charts. The concept of
nodal “zones” has been introduced to make such classification relevant to those dealing
with bulky nodal deposits that transgress the boundaries of individual nodal stations.12
h. For the first time we have introduced a precise definition of “visceral pleural invasion,”
a long-standing T2 descriptor, with recommendations on the use of elastic stains to
determine this feature.10
There are consequential changes to some stage groupings6:
a. The smaller T2 tumors, those 3 cm but 5 cm, become T2a, and T2a N1 M0 cases
are down-staged from stage IIB to IIA.
b. The larger T2 tumors, those that are 5 cm but 7 cm become T2b and those tumors
7 cm become T3, are up-staged in the new TNM subsets they now join; T2b N0 M0
cases from stage IB to IIA, T3 N0 M0 from IB to IIB and T3 N1 M0 from IIB to IIIA.
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c. Those cases with additional tumor nodules in the lobe of
the primary, now T3 and not T4, will be down-staged from
stage IIIB; if N1 or N2 to stage IIIA, and if N0 to stage
IIB.
d. Those cases with additional tumor nodules in other ipsi-
lateral lobe(s), now T4 and not M1, will be down-staged
from stage IV; if N2 or N3 to stage IIIB, and if N0 or N1
to stage IIIA.
e. Tumors that are T4 due to other features will be down-
staged if N0 or N1 from stage IIIB to stage IIIA.
f. Tumors associated with pleural or pericardial nodules/
effusions become M1a instead of T4 and are consequently
up-staged from IIIB to stage IV.
Some of these changes to the descriptors and stage
groupings will have consequences for established treatment
algorithms. Should those larger tumors that are node negative
and which move from stage IB to stages IIA or IIB be consid-
ered for adjuvant chemotherapy after complete resection? The
evidence to date has shown a survival benefit to such an
approach in stage II cases15 but the evidence for this approach
in stage IB is controversial and its use is unproven.16 We
should remember that these trials were conducted at a time
when stage II consisted of N1 cases, and trials will be
necessary before one can assume such benefit in N0 cases.
Similarly, there will be a greater emphasis on the role of
surgery, probably in a multimodality setting, in cases that
have been down-staged from stage IV or IIIB to IIIA or IIB.
Common sense will restrict such calls to selected cases, but
again trials will be needed to show the possible benefit of
such surgery. We are in for an exciting time!
The IASLC has prepared a range of educational prod-
ucts to inform the lung cancer community of these changes.
The Staging Handbook in Thoracic Oncology provides a
handy pocket book describing the main features of the 7th
edition, the more extensive Staging Manual in Thoracic
Oncology contains additional background information, ex-
planatory material and wider clarification such as that found
in the TNM Supplement produced by the International Union
Against Cancer.17 There are pocket laminates and larger
posters providing an aide memoire of the key features. The
IASLC has commissioned Dr. Aletta Frasier to produce
drawings for a TNM Atlas of the new descriptors and a CT
Atlas of axial, coronal and sagital images which are included
in these publications. There will be a wealth of information
on the IASLC web site (www.iaslc,org), available to mem-
bers to down load, with PowerPoint presentations and sup-
porting data and survival graphs.
The process by which TNM in Lung Cancer evolves
has been changed irrevocably, and the IASLC has secured a
central role in future revisions for the whole of the Thoracic
Oncology community. The 7th edition of TNM is based upon
the largest data base ever accrued, with global representation
and cases treated by all modalities of care. There has been
more extensive analysis, and internal and external validation
never before used to support changes to the TNM classifica-
tion. However, such a retrospective data base has its limita-
tions and failings. There are shortcomings in the geographical
accrual and still an unrepresentative dominance of surgically
treated cases. The data were not collected for the primary
purpose of TNM analysis and, with so many languages,
quality control was limited. The routine use of PET scanning
postdated the period of data collection. The IASLC proposes
to improve these aspects in time for the 8th edition of TNM.
A prospective data set has been agreed,11 funding has been
secured for the 7-year cycle leading up to the 8th edition. A
web-based data collection system is being developed and
tested to make data submission easier for those who collab-
orate in this next phase. Data collection has been expanded to
incorporate neuro-endocrine tumors18 and mesothelioma.
However, ultimately the success of our efforts will depend
upon the continued and expanded support we receive from
colleagues around the world.
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